Showing 1651-1660 of 1841 results for "".
- Focus Vitamins Launches New Daily Eye Health Supplement: Focus Luteinhttps://modernod.com/news/focus-vitamins-launches-new-daily-eye-health-supplement-focus-lutein/2482758/Focus Vitamins, a physician-founded nutraceutical company under Covalent Medical, has announced the launch of 'Focus Lutein,' a daily eye health supplement designed to support long-term vision and defend against age-related changes.
- Virtual Vision Health Launches Visual Acuity Testing on Virtual Eye VR Platformhttps://modernod.com/news/virtual-vision-health-launches-visual-acuity-testing-on-virtual-eye-vr-platform/2482663/Virtual Vision Health announced the launch of visual acuity testing on its Virtual Eye VR platform. According to Virtual Vision, with patients needing regular visual acuity testing to monitor changes and maintain overall eye health, this feature ensures prov
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- Annexon Announces Topline Data from Phase 2 Trial of ANX007 in Geographic Atrophyhttps://modernod.com/news/annexon-announces-topline-data-from-phase-2-trial-of-anx007-in-geographic-atrophy/2481637/Annexon announced topline results from its ARCHER phase 2 trial of ANX007 in patients with geographic atrophy (GA). The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Contact Lens Institute Unveils Nationwide “See Tomorrow Campaign;” Industry Launch Event Slated for July 22https://modernod.com/news/contact-lens-institute-unveils-nationwide-see-tomorrow-campaign-industry-launch-event-slated-for-july-22/2479347/A new professional and consumer initiative from the Contact Lens Institute (CLI) is poised to reveal insights about how patient psyches surrounding vision, health care and their lives have changed over the course of the pandemic—and the ensuing opportunities for the optometry community. The CLI <